These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38735683)

  • 21. Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.
    Wang X; Popplewell LL; Wagner JR; Naranjo A; Blanchard MS; Mott MR; Norris AP; Wong CW; Urak RZ; Chang WC; Khaled SK; Siddiqi T; Budde LE; Xu J; Chang B; Gidwaney N; Thomas SH; Cooper LJ; Riddell SR; Brown CE; Jensen MC; Forman SJ
    Blood; 2016 Jun; 127(24):2980-90. PubMed ID: 27118452
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
    Schubert ML; Schmitt A; Sellner L; Neuber B; Kunz J; Wuchter P; Kunz A; Gern U; Michels B; Hofmann S; Hückelhoven-Krauss A; Kulozik A; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
    BMJ Open; 2019 May; 9(5):e026644. PubMed ID: 31110096
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.
    Hirayama AV; Gauthier J; Hay KA; Voutsinas JM; Wu Q; Gooley T; Li D; Cherian S; Chen X; Pender BS; Hawkins RM; Vakil A; Steinmetz RN; Acharya UH; Cassaday RD; Chapuis AG; Dhawale TM; Hendrie PC; Kiem HP; Lynch RC; Ramos J; Shadman M; Till BG; Riddell SR; Maloney DG; Turtle CJ
    Blood; 2019 Apr; 133(17):1876-1887. PubMed ID: 30782611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia.
    Li J; Wu Z; Zhao N
    Adv Ther; 2019 Oct; 36(10):2881-2894. PubMed ID: 31428935
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study.
    Frank MJ; Baird JH; Kramer AM; Srinagesh HK; Patel S; Brown AK; Oak JS; Younes SF; Natkunam Y; Hamilton MP; Su YJ; Agarwal N; Chinnasamy H; Egeler E; Mavroukakis S; Feldman SA; Sahaf B; Mackall CL; Muffly L; Miklos DB;
    Lancet; 2024 Jul; 404(10450):353-363. PubMed ID: 38996463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Toxicity of CD19 Chimeric Antigen Receptor T Cell Therapy for Lymphoma in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis.
    Yamshon S; Gribbin C; Chen Z; Demetres M; Pasciolla M; Alhomoud M; Martin P; Shore T
    Transplant Cell Ther; 2024 Jan; 30(1):73.e1-73.e12. PubMed ID: 37279856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells.
    Park JH; Romero FA; Taur Y; Sadelain M; Brentjens RJ; Hohl TM; Seo SK
    Clin Infect Dis; 2018 Aug; 67(4):533-540. PubMed ID: 29481659
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma.
    Jackson Z; Roe A; Sharma AA; Lopes FBTP; Talla A; Kleinsorge-Block S; Zamborsky K; Schiavone J; Manjappa S; Schauner R; Lee G; Liu R; Caimi PF; Xiong Y; Krueger W; Worden A; Kadan M; Schneider D; Orentas R; Dropulic B; Sekaly RP; de Lima M; Wald DN; Reese JS
    Front Immunol; 2020; 11():1941. PubMed ID: 32849651
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis.
    Anagnostou T; Riaz IB; Hashmi SK; Murad MH; Kenderian SS
    Lancet Haematol; 2020 Nov; 7(11):e816-e826. PubMed ID: 33091355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interaction kinetics with transcriptomic and secretory responses of CD19-CAR natural killer-cell therapy in CD20 resistant non-hodgkin lymphoma.
    Ravi D; Sarkar S; Purvey S; Passero F; Beheshti A; Chen Y; Mokhtar M; David K; Konry T; Evens AM
    Leukemia; 2020 May; 34(5):1291-1304. PubMed ID: 31772298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The clinical outcomes of fresh versus cryopreserved CD19-directed chimeric antigen receptor T cells in non-Hodgkin lymphoma patients.
    Su T; Ying Z; Lu XA; He T; Song Y; Wang X; Ping L; Xie Y; Tu M; Liu G; Qi F; Ding Y; Jing H; Zhu J
    Cryobiology; 2020 Oct; 96():106-113. PubMed ID: 32721392
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials.
    Leahy AB; Newman H; Li Y; Liu H; Myers R; DiNofia A; Dolan JG; Callahan C; Baniewicz D; Devine K; Wray L; Aplenc R; June CH; Grupp SA; Rheingold SR; Maude SL
    Lancet Haematol; 2021 Oct; 8(10):e711-e722. PubMed ID: 34560014
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma.
    Liu H; Lei W; Zhang C; Yang C; Wei J; Guo Q; Guo X; Chen Z; Lu Y; Young KH; Lu Z; Qian W
    Clin Cancer Res; 2021 Jan; 27(2):473-484. PubMed ID: 33028589
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
    Cappell KM; Sherry RM; Yang JC; Goff SL; Vanasse DA; McIntyre L; Rosenberg SA; Kochenderfer JN
    J Clin Oncol; 2020 Nov; 38(32):3805-3815. PubMed ID: 33021872
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
    Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE).
    George P; Dasyam N; Giunti G; Mester B; Bauer E; Andrews B; Perera T; Ostapowicz T; Frampton C; Li P; Ritchie D; Bollard CM; Hermans IF; Weinkove R
    BMJ Open; 2020 Feb; 10(2):e034629. PubMed ID: 32041862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myocardial strain is associated with adverse cardiac events in patients treated with chimeric antigen receptor (CAR) T-cell therapy.
    Patel NP; Dalal PJ; Meng Z; Baldridge AS; Cascino GJ; Sunderraj A; Sinha A; Karmali R; Feinstein MJ; Akhter N
    Eur J Haematol; 2024 Jan; 112(1):102-110. PubMed ID: 37649240
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dermatologic Adverse Events Associated With Chimeric Antigen Receptor T-Cell Therapy: A Pharmacovigilance Analysis of the FDA Reporting System.
    Storgard R; Dusza S; Shouval R; Scordo M; Markova A
    Transplant Cell Ther; 2024 Oct; 30(10):1035.e1-1035.e7. PubMed ID: 38945480
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy.
    Ruark J; Mullane E; Cleary N; Cordeiro A; Bezerra ED; Wu V; Voutsinas J; Shaw BE; Flynn KE; Lee SJ; Turtle CJ; Maloney DG; Fann JR; Bar M
    Biol Blood Marrow Transplant; 2020 Jan; 26(1):34-43. PubMed ID: 31605820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of acute lymphoblastic leukaemia with the second generation of CD19 CAR-T containing either CD28 or 4-1BB.
    Li S; Zhang J; Wang M; Fu G; Li Y; Pei L; Xiong Z; Qin D; Zhang R; Tian X; Wei Z; Chen R; Chen X; Wan J; Chen J; Wei X; Xu Y; Zhang P; Wang P; Peng X; Yang S; Shen J; Yang Z; Chen J; Qian C
    Br J Haematol; 2018 May; 181(3):360-371. PubMed ID: 29637550
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.